Halozyme Therapeutics Inc. HALO

NAS: HALO | ISIN: US40637H1095 24/03/2025

64,02 USD (-1,75%)

(-1,75%) 24/03/2025

Grafiek Halozyme Therapeutics Inc.

Grafiek Halozyme Therapeutics Inc.

1 dag1d -1,75%
1 week1w 1,70%
1 maand1m 9,44%
3 maanden3m 34,67%
6 maanden6m 13,91%
1 jaar1j 58,39%
5 jaar5j 285,43%

Halozyme Therapeutics Inc. in het nieuws

Toon enkel gratis nieuws

13 september 2024 · Halozyme Announces FDA Approval of Roche's Tecentriq Hybreza™ With ENHANZE® for Multiple Types of Cancer · Persbericht

28 augustus 2024 · Halozyme to Present at Upcoming Investor Conferences · Persbericht

6 augustus 2024 · Halozyme Reports Second Quarter 2024 Financial And Operating Results · Persbericht

23 juli 2024 · Halozyme to Report Second Quarter 2024 Financial and Operating Results · Persbericht

25 juni 2024 · Halozyme Announces Roche's OCREVUS® SC with ENHANZE® Receives European Commission Approval for Relapsing and Primary Progressive Multiple Sclerosis · Persbericht

21 juni 2024 · Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo Co-Formulated with ENHANZE® for Chronic Inflammatory Demyelinating Polyneuropathy · Persbericht

6 juni 2024 · Halozyme Raises Full Year 2024 Financial Guidance and Updates 5-Year Financial Outlook · Persbericht

5 juni 2024 · Halozyme Announces Issuance of New European Patent for ENHANZE® Drug Delivery Platform · Persbericht

4 juni 2024 · Halozyme to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference · Persbericht

21 mei 2024 · Halozyme Announces Bristol Myers Squibb Received Updated Action Date from the U.S. Food and Drug Administration for Subcutaneous Nivolumab Co-Formulated with ENHANZE® · Persbericht

Profiel Halozyme Therapeutics Inc.

Gezondheidstechnologie

Productie van biologische producten

Website: www.halozyme.com

Hoofdzetel: San Diego, California Verenigde Staten

CEO: Helen Torley

Werknemers: 452

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe